| Colusa Medical Center | |
| 199 E Webster Street, Colusa, California 95932 | |
| (530) 619-0800 | |
| Not Available |
| Name | Colusa Medical Center |
|---|---|
| Type | Acute Care Hospital |
| Location | 199 E Webster Street, Colusa, California |
| Ownership | Proprietary |
| Emergency Services | Yes |
| Medicare ID (CCN) | 050783 |
| NPI Number | 1063543510 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5822 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1124159611 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Doing Business As | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1144215427 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E. Webster Street, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital - Rural |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1164930707 |
| Organization Name | CALIFORNIA SPECIALTY HOSPITAL SOUTH |
| Address | 21530 Pioneer Blvd, Hawaiian Gardens, CA 90716 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 209-505-7464 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1205247624 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E. Webster Street, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1265940894 |
| Organization Name | CALIFORNIA SPECIALTY HOSPTIAL NORTH |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 209-505-7464 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1376676569 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1376712281 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Doing Business As | WILLIAMS URGENT CARE MEDICAL CENTER |
| Address | 501 E Street, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1386777605 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1659404820 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1831368745 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Doing Business As | COLUSA HEALTH CLINIC |
| Address | 2967 Davison Ct Ste A, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| NPI Number | 1952434391 |
| Organization Name | COLUSA REGIONAL MEDICAL CENTER |
| Address | 199 E Webster St, Colusa, CA 95932 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 530-458-5821 |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
| Able to receive lab results electronically | No |
| Able to track patients' lab results, tests, and referrals electronically between visits | No |
News Archive
In newly released research, 79 migraine sufferers were followed for at least five years after having undergone detection of migraine "trigger sites" and surgery. The new data finds promising outcomes for treating trigger sites surgically for migraine headaches resulting in elimination of pain for those afflicted with the condition.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.
Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
OFFLU, the OIE/FAO joint network of expertise on avian influenza, will systematically make avian influenza virus sequences accessible to the entire scientific community.
› Verified 2 days ago
Colusa Medical Center Acute Care Hospital Location: 199 E Webster Street, Colusa, California 95932 Phone: (530) 619-0800 |